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ABSTRACT
Prognosis of breast carcinoma is influenced by age, tumor size, histological 
grade and type, lymph node status, as well as metastasic status. Chemokine 
receptor CXCR-4 with its ligand, CXCL-12, may play an important role in 
metastasis of breast carcinoma. However, the role of CXCL-12 mRNA as a 
prognostic factor and a therapeutic target of human breast cancer remains 
controversial. This study aimed to investigate the level of CXCL-12 mRNA 
expression in lymph nodes of patients with invasive ductal breast carcinoma 
and the difference within the prognostic factors. Axillary lymph nodes 
obtained from 50 cases of invasive ductal breast carcinoma, were divided into 
two groups, with and without lymph node metastasis. Each group consisted 
of 25 cases. Total RNA was extracted from formalin-fixed paraffin-embedded. 
The CXCL-12 mRNA expression was examined using qRT-PCR method. The 
mean differences between the two groups were analyzed using Mann-Whitney 
test. The differences between CXCL-12 mRNA expression and each prognostic 
factor ware analyzed using Mann-Whitney comparison test. CXCL-12 mRNA 
expression was significantly higher in the lymph node of patients with 
metastasis of breast carcinoma compared to the non-metastasis cases (p<0.01). 
There were significant differences between CXCL-12 mRNA expression with 
poorly histological grade (p=0.003), bigger primary tumor size (p=0.005) and 
age of ≥45 y.o (p=0.012) in the metastatic group, but there were no significant 
differences between both age of <45 and ≥45 y.o.This study suggests that the 
higher CXCL-12 mRNA expression level are associated with bigger tumor size 
and poor differentiation in breast cancer patient with lymph nodes metastasis.
ABSTRAK
Prognosis karsinoma payudara dipengaruhi oleh usia, ukuran tumor, derajat 
dan tipe histologis, status kelenjar getah bening serta status metastasis. 
Reseptor kemokin CXCR-4dengan ligannya, CXCL-12 berperan penting dalam 
metastasis karsinoma payudara. Namun peran CXCL-12 mRNA sebagai faktor 
prognostik dan target terapi kanker payudara masih kontroversial. Penelitian 
ini bertujuan untuk mengkaji tingkat ekspresi mRNA CXCL-12 pada kelenjar 
getah bening pasien karsinoma payudara duktal invasif dan perbedaan 
faktor prognostiknya. Kelenjar getah bening aksila diperoleh dari 50 kasus 
karsinoma payudara duktal invasif, dibagi menjadi dua kelompok, dengan 
dan tanpa metastasis kelenjar getah bening. Setiap kelompok terdiri dari 25 
kasus.RNA total diekstraksi dari formalin-fixed paraffin-embedded. Ekspresi 
mRNA CXCL-12 diperiksa dengan metode qRT-PCR. Perbedaan rata-rata antara 
kedua kelompok dianalisis menggunakan uji Mann-Whitney. Perbedaan 
antara ekspresi mRNA CXCL-12 dan masing-masing faktor prognostik 
dianalisis dengan uji perbandingan Mann-Whitney. Ekspresi mRNA CXCL-12 
lebih tinggi secara nyata pada kelenjar getah bening pasien dengan metastasis 
karsinoma payudara dibandingkan dengan kasus non-metastasis (p <0,01). 
Ada perbedaannyata antara ekspresi CXCL-12 mRNA dengan derajat histologis 
yang buruk (p = 0,003), ukuran tumor primer yang lebih besar (p = 0,005) dan 
usia ≥ 45 tahun (p = 0,012) pada kelompok metastasis, tetapi tidak adaperbedaan 
nyata antara usia <45 dan≥ 45 tahun. Penelitian ini menunjukkan bahwa 
tingkat ekspresi CXCL-12 mRNA yang lebih tinggi berkaitan dengan ukuran 
tumor yang lebih besar dan diferensiasi yang buruk pada pasien kanker 
payudara dengan metastasis kelenjar getah bening.
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INTRODUCTION
The prevalence of breast cancer 
in Indonesia according tobasic health 
research (Riset Kesehatan Dasar/
Riskesdas) in 2013 was the highest after 
cervical cancer (0.5 per 1000 inhabitants). 
In Yogyakarta Special Province, the 
prevalence of breast cancer was 2.4 per 
1,000 inhabitants.1 The trend of female 
breast cancer was increasing during 
2013- 2018. Globocan, the International 
Agency for Research on Cancer (IARC), 
in2018 estimated the incidence of female 
breast cancer in Indonesia was 42.1 
per 100,000 andthe mortality rate was 
17.0 per 100,000.2 The most common 
type of breast cancer is  invasive ductal 
carcinoma non-special type (NST) as 
much as 59%.3
Metastasis is a major cause of 
mortality and morbidity in breast 
carcinoma. The metastasis has a 
distinctive pattern and has no correlation 
with blood flow patterns. However, it 
may show preferential homing, cell 
adhesion, survival and proliferation of 
cancer cells in specific tissues and organs, 
such as lymph nodes, lungs, bones, and 
liver. Several factors have shown to play 
a role in metastatic carcinoma of the 
breast, including the chemokine receptor 
CXCR4, and its ligand CXCL12.
CXCL12 or stromal cell-derived 
factor (SDF-1) is a member of the CXC 
chemokine family. Itis derived from 
cloned murine bone marrow and 
characterized as a pre-cell B growth-
stimulating factor. SDF-1 is activated 
through CXC chemokine receptor 
(CXCR4), whichis a physiological receptor 
for SDF-1 and plays a role in chemotaxis, 
haematopoiesis, vasculogenesis, and 
metastasis. CXCR4 has been recognized to 
play a role in tumor cell homing to specific 
organs.4 Activation of CXCR4 induces 
signal transduction pathways of cancer 
cells initiating the process of metastasis 
through cytoskeletal changes, actin 
polymerization,5 pseudopodia formation, 
endothelial cell adhesion, migration, and 
proliferation.6  In addition, axis CXCR4-
CXCL12 is involved in repair and tissue 
regeneration. The repair of ischemic 
lesion involves selective recruitments of 
local or circulating progenitor cells.
Hypoxia-inducible factor-1 (HIF-1), 
is the main mediatorin tissue hypoxia, 
which induces the expression of CXCL12 
in ischemic tissue. It inducesthe CXCL12 
on endothelial cells by attract circulating 
stem cells and progenitor cells to the 
lesion area. During tissue regeneration, 
CXCL12 expression will return to normal 
after the oxygen tension is normalized.7 
In addition, HIF-1 also can improve the 
expression and function of CXCR4 in 
normal cells and malignant cells.8 CXCR4 
in breast carcinoma is expressed on tumor 
cells of primary and metastatic lesions, 
whereas CXCL12 is produced in many 
organs and tissue metastasis targets. 
CXCL4-CXCR12 axis affects angiogenesis, 
tumor cell proliferation, apoptosis, and 
mediates tumor cells to metastasize 
into the target organ. This chemokine 
can be examined semiquantitatively 
using immunohistochemical techniques 
or quantitatively using qRT-PCR 
(quantitative real time PCR).9-12
CXCL12 mRNA expression 
significantly upregulated in 
miofibroblast of invasive breast 
carcinoma, compared to that of 
miofibroblast in normal breast tissue. 
Besides direct effects on breast carcinoma 
cells, CXCL12 is also as a mediator 
to attract the circulating endothelial 
progenitor cells in the process of 
angiogenesis.13  The role of CXCR 
4-CXCL12 axis in the metastasis process 
also occurs in other organ malignancies, 
including brain tumor cells (neuronal 
and glial tumors),14 neuroblastoma,15 
colorectal cancer,16 prostate cancer,17 
melanoma,18 and ovarian cancer.19
CXCR4 mRNA expression in primary 
tumors of colorectal cancer20 and 
melanoma18 is correlated with their 
recurrence, metastasis, and survival. 
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Research on gastric carcinoma has 
shown a significant difference in mRNA 
expression levels of SDF-1 (CXCL12) 
between lymph nodes with metastasis 
and normal lymph nodes. Positive SDF-1 
mRNA expression in lymph nodes with 
metastatic  gastric carcinoma isconsistent 
with the positive CXCR4 mRNA 
expression in carcinoma gaster.21 Studies 
published that emphasize SDF-1 and 
CXCR4  in  breast carcinoma have been 
performed in vitro, however the study 
of prognostic and therapeutic molecular 
targets CXCL12/SDF-1 in human breast 
carcinoma still has been very limited. 
This study aimedto investigate the 
differencesin mRNA expression levels 
of CXCL12 in lymph nodes of patients 
with breast carcinoma with and without 
lymph nodes metastasis, as well as its 
relation with histological grade, age, and 
size of the primary tumor, quantitatively 
using qRT-PCR technique.
MATERIALS AND METHODS
Patients
This research was a retrospective 
observational non-analytical experimental 
cross sectional approachconducted in 
the Department of Pathology, Faculty of 
Medicine, Public Health and Nursing, 
Universitas Gadjah Mada and Dr.Sardjito 
General Hospital, Yogyakarta. Subjects 
were lymph node tissue paraffin 
blocks of breast carcinoma patients 
from 50 patients, who were selected by 
consecutive sampling between 2014 and 
2015. The samples weregrouped into 
two groups lymph nodes with cancer 
cell infiltrationof breast carcinoma 
andthose without   cancer  cell 
infiltation.  Each group consisted of 25 
patients. The inclusion criteria of this 
study ware women with invasive ductal 
breast carcinoma of NST, modified 
radical mastectomy breast surgery, had 
complete clinicopatologic data and >2mm 
cancer cell in formalin-fixed paraffin 
embedded. The exclusion criteria were 
men, with recurrent cases, incomplete 
supporting data and without propper 
formalin fixed paraffin embedded. This 
study was approved by the Medical and 
Health Research Committee, Faculty of 
Medicine, Public Health and Nursing, 
Universitas Gadjah Mada, Yogyakarta. 
Protocol of study
Data on the clinicopathological 
characteristics were extracted from 
the medical records. Characteristic 
variables of patients were age using cut 
off 45 years old, with <45 versus ≥45 
y.o, primary tumor size using ≤2 cm 
versus >2 cm, and histological grade or 
tumor differentiation. Since there was 
no good histological grade in this panel, 
the patients were classified as moderate 
and poor histological grade. The CXCL12 
mRNA expression levels was obtained 
byqRT-PCR.
The extraction of RNA from paraffin 
embedded-samples were used in this 
study. The samples were prepared 
from the paraffin embedded-tissue 
that cut into 5 slices of 6-µm sections 
using a microtome. FavorPrepTM 
Tissue Total RNA Mini Kit was used 
for RNA extraction according to the 
manufacturer’s instructions. Tumor 
samples were taken from areas of 
histopathologically confirmed invasive 
ductal carcinoma. Weutilized > 2mm in 
the greatest dimension or ≥80% tumor 
cell in lymph node tissue and scraped off 
the normal tissue. Paraffin was removed 
by extracting three times with Xylol 
for @ 10 min, 3 min, 3 min, followed 
byethanol absolute twice for 3 min. Cell 
or tissue was lysed using 350µL FARB 
buffer and 3.5µL β-mercaptoethanol, 
incubate at room temperature for 3 min, 
centrifuge for 30 sec at 1000 rpm. RNA 
was bound by 400µL of 70% ethanol 
(RNase free), centrifuge at 14000 rpm 
for 1 min. The RNA pellet was washed 
with 500 and 750µL wash buffer twice, 
centrifuge at 14000 rpm for 1 min, finally 
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for RNA elution dissolved in 50µL RNase-
free water and centrifuge at 14000 rpm 
for 1 min. RNA concentration and purity 
were determined using a NanoDrop 
spectrophotometer. qRT-PCR was 
performed using the DT-Lite Real-Time 
PCR System (DNA Technology) with KAPA 
SYBR®FAST One- Step qRT- PCR Kit fast. 
GAPDH was used as the housekeeping 
gene and CXCL12 expression level was 
investigated using the specific primer.
GAPDH sequence was fw 5’-GCA TCC 
TGG GCT ACA CTG AG-3 ‘and rev 5’-TCC 
ACC ACC CTG TTG CTG TA-3’. CXCL12 
sequence was fw 5’-GAT TGT AGC CCG 
GCT GAA GA-3 ‘and rev 5’-TTC GGG TCA 
ATG CAC ACT TGT-3’. Cycling condition 
was reverse transcription 5 min at 42ºC, 
enzyme inactivation 3 min at 95ºC, 
followed by 40 cycles of denaturation 3 
sec at 95ºC and 20 sec extension at 60ºC, 
according to instrument guidelines. 
CXCL12 expression levels were assessed 
according to the standard curve method 
with 2-ΔΔCT formula. ∆CT= PCR score of 
CXCL12 – PCR score GAPDH. ∆∆CT= ∆CT 
of tumor sample –∆CT normal tissue.22
Statistical analysis
The mean of CXCL-12 mRNA 
expression level between two groups 
and the differences in prognostic 
factors were analyzed using a Mann-
Whitney test. A p < 0.05 were considered 
statistically significant. 
RESULTS
Characteristics of patients
The characteristic features of 50 
female patients with breast carcinoma 
are in TABLE 1. The mean age at 
diagnosis was 51.8 + 11.2 y.o. (median 
51 yr), 36 patients (72%) were ≥ 45 yr 
and 14 patients (28%) were <45 yr. The 
smallest tumor size was 0.80 cm and 
the largest size was 15 cm. Those with 
poor histological grade were 41 patients 
(82%), 9 patients (18%) with moderate 
grade, and there was no sample with 
good histological grade.The number of 
patients with lymph node metastatic 
breast carcinoma were more frequent at 
the age of≥45 yr, having primary tumor 
size >2 cm and a poor histological grade.
TABLE 1. Characteristic of patient with breast carcinoma
Variable
Frequency (%)
 Total 
(%)Non lymp node 
metastasis
Lymph node 
Metastasis
Age (yr)
•	< 45 8 (32) 6 (24) 14 (28)
•	 ≥ 45 17 (68) 19 (76) 36 (72)
Primary tumor size (cm)
•	 ≤ 2 6 (24) 3 (12) 9 (18)
•	> 2 19 (76) 22 (88) 41 (82)
Histological grade
•	2 6 (24) 3 (12) 9 (18)
•	3 19 (76) 22 (88) 41 (82)
CXCL12 mRNA expression by groups 
of lymph node metastasis
The results of the qRT-PCR analysis 
is shown in FIGURE 1 and 2. The mean 
of CXCL12 mRNA expression in the 
metastatic group (47.70±9.01)was 
significantly higher (p=0.007) than that 
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inthe non-metastasis group (19.01±4.80). 
The lowest CXCL12 mRNA expression in 
the metastasis group was 1.23 fold and 
the highest was 168.89 fold, compared 
with the internal control. In the non-
metastasis group, the lowest CXCL12 
mRNA expression was 1.41 fold and 
the highest was 119.42 fold compared 
with internal control. Most of the tumor 
tissues had increased level, compared 
to normal tissue that was considered a 
1-fold expression level. 
The wide range might be caused 
by some factors, the most likely cause 
was the use of paraffin-embedded 
formalin-fixed tissue to analyzemRNA 
expression. Formalin fixation induces 
RNA molecules breakdown into small 
fragment, cross-linkage of nucleic acids 
with protein, leading to inefficient 
reverse transcription reaction.23 The 
duration of fixation, storage,and 
extraction techniques impact the quality 
of RNA extracted from fixed and paraffi-
embedded tissues.
FIGURE 1. Dependence of FAM channel 
fluorescences on cycle number. 
Each line represents the 
expression of CXCL12 mRNA in 
lymph node metastasis.
FIGURE 2. Dependence of FAM channel 
fluorescences on cycle number. 
Each line represents the 
expression of CXCL12 mRNA in 
lymph node without metastasis.
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FIGURE 3. Box plot CXCL12 mRNA expression in 
lymph nodes with and without metastasis 
of breast carcinoma  
The differences CXCL12 mRNA 
expression in both groups based 
on age, primary tumor size and 
histological grade 
Mann-Whitney comparison test in 
TABLE 2 shows significant differences in 
CXCL12 mRNA expression level  between 
lymph nodes with metastatic carcinoma 
of the breastand without metastasis at 
age≥45 yr (p = 0.012), primary tumor size 
>2 cm (p = 0.005) and the poor histological 
grade (p = 0.003). However, there was no 
significant difference in CXCL12 mRNA 
expression level in both groups at age 
<45 yr (p = 0.370), primary tumor size <2 
cm (p = 0.80) and moderate histological 
grade (p = 0.360).
TABLE 2. The differences CXCL12 mRNA expression between lymph nodes with and 
without metastasis based on age, primary tumor size and histological grade
Characteristics
Total 
(%)
Non metastasis Metastasis
p
n (%)
Mean 
CXCL12
n (%)
Mean 
CXCL12
Age (yr)
•	< 45 14 (28) 8 (32) 14.5±2.8 6 (24) 28.4±10.4 0.370
•	≥45 36 (72) 17 (68) 21.1±7.0 19 (76) 53.8±11.1 0.012
Primary tumor size (cm)
•	≤ 2 9 (18) 6 (24) 14.4±6.0 3 (12) 10.3±2.6 0.800
•	> 2 41 (82) 19 (76) 20.5±6.1 22 (88) 52.8±9.7 0.005
Histologic grade
•	2 9 (18) 6 (24) 15.2±5.8 3 (12) 8.7±6.9 0.360
•	3 41 (82) 19 (76) 20.2±6.1 22 (88) 53.0±9.7 0.003
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The differences between each 
prognostic factor of lymph nodes 
metastasis and without metastasis 
groups are presented in TABLE 3. A 
significant differences in CXCL12 mRNA 
expression between moderate and poor 
histological grade in the group with 
lymph node metastasis (p = 0.030) was 
observed, but not in the non-metastasis 
one (p = 0.850). A significant difference in 
CXCL12 mRNA expression level between 
the primary tumor size ≤2 cm and >2 
cm in metastasis group (p = 0.04) was 
observed, but not in the non-metastasis 
one (p = 0.730). The tumor size >2 cm 
and a poor histological grade increased 
the mean of CXCL12 mRNA expression 
level by 52.8±9.7 fold in tumor size and 
53.0±9.7 fold  in histological grade.
TABLE 3. The difference between the ages of CXCL12 mRNA expression, pimer tumor 
size, histological grade in the group with lymph node metastasis and 
withoutmetastasis
Characteristics
Non metastasis
p
Metastasis
p
n (%)
Mean 
CXCL12
n (%)
Mean 
CXCL12
Age (yr)
•	< 45 8 (32) 14.5±2.8
0.82
6 (24) 28.4±10.4
0.590
•	≥ 45 17 (68) 21.1±7.0 19 (76) 53.8±11.1
Primary tumor size(cm)
•	≤ 2 6 (24) 14.4±6.0
0.73
3 (12) 10.3±2.6
0.040
•	>2 19 (76) 20.5±6.1 22 (88) 52.8±9.7
Histologic grade
•	2 6 (24) 15.2±5.8
0.85
3 (12) 8.7±6.9
0.030
•	3 19 (76) 20.2±6.1 22 (88) 53.0±9.7
DISCUSSION
CXCL12,  a ligand of the chemokine 
receptor CXCR4, plays an important 
role in metastatic breast carcinoma. 
CXCL12-CXCR4 axis affects angiogenesis, 
tumor cell proliferation, apoptosis, and 
mediates tumor cells to metastasize 
into the target organ. In this study, 
CXCL12 mRNA expression of the 
axillary lymph node with invasive 
ductal breast carcinoma was observed 
by using qRT-PCR. The choice of qRT-
PCR analyses was also guided by the 
consideration that other techniques 
such as immunohistochemical staining 
confirmed the expression of CXCL12 
at the protein level, considering the 
staining intensity and area extent. 
CXCL12 appears in most tumor cells and 
in stromal cells, therefore more difficult 
to quantify. However, qRT-PCR does not 
reveal the cell type of expression. The 
increased mean level of CXCL12 mRNA 
expression in lymph nodes metastatic 
breast carcinoma was significantly 
higher (p=0.007) compared to that 
without metastasis. This supports the 
interaction between CXCL12 and CXCR4 
as its receptor, possibly causing breast 
carcinoma cells to migrate to lymph nodes 
that have a high number of chemokines.24 
Similar findings were obtained  by  Kang 
et al.25 and Shim et al.9  In contrast, 
previous studies demonstrated that 
CXCL12 expression is higher  in  lymph 
nodes without metastasis of breast 
carcinoma. However, the study was 
conducted with a cohort microarray and 
immunohistochemical methods with a 
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total sample of 249 cases.10
Complex CXCL12-CXCR4 can 
significantly increase the migration 
speed and the invasive feature of breast 
carcinoma cells in vitro.25 The study of 
CXCL12 expression in lymph node of 
metastatic carcinoma of extra-mammary 
Paget’s disease showed an increased 
expression of CXCL12 in tumor-
associated lymphatic endothelium 
and endothelial limphangiogenic in 
the subcapsular sinus tumor- draining 
lymph nodes, whereas CXCR4 is more 
expressed on the cell tumor.26 When 
tumor cells or stromal tumors secrete 
lymphangiogenic growth factors, such 
as VEGF-C or VEGF-D, attracted to the 
lymphatic vessels expressing VEGFR-3 
in the primary tumor, chemokines 
secreted by lymph vessels or lymph 
nodes will attract the migration of tumor 
cells expressing chemokine receptors 
to the lymph nodes.27 This shows that 
CXCL12 and VEGF synergistically 
increase the angiogenic process. Other 
studies have shown CXCL12 can induce 
neovascularization in vivo and the 
formation of new blood vessels in rat 
aorta ex vivo.28 Thus CXCL12 can be a 
potential marker for metastatic process 
in lymph node.
Vasa lymphatic preferentially 
facilitates metastasis by providing 
pathways to spread tumor cells than 
blood vessels due to discontinuous 
basement membrane, loose cell junction 
and low flow rate. Therefore, it can reduce 
pressure and increase the survival of 
tumor cells. Thus lymphatic metastasis 
in breast carcinoma can be an important 
predictor. Migration of tumor cells to 
target organs occurs through chemotactic 
effects of  CXCL12-CXCR4 axis. The 
increase of CXCL12 mRNA expression 
in target organs is associated with 
prognostic factors of breast carcinoma. 
The prognostic factors studied were age, 
primary tumor size, and histological 
grade or tumor differentiation. CXCL12 
mRNA expression in poor histological 
grade showed significant differences 
between groups of lymph nodes with 
metastatic breast  carcinoma and 
without  metastasis (p = 0.030). These 
results are similar to previous studies 
demonstrating  high levels of SDF-1 mRNA 
expression in breast carcinoma with 
poor histological grade and moderate 
compared to the well-differentiated 
grade.25 It showed that CXCL12 (SDF-1) 
increases in aggressive tumors.
The present study showedthat 88% 
of samples in the lymph nodes metastasis 
group exhibita bigger primary tumor 
size (> 2 cm). Of this, 80% were having 
poor histological grade, with CXCL12 
mRNA expression higher than the non-
metastasis group. In lymph nodes, 
metastasis group with primary tumor 
size >2 cm, the differences in CXCL12 
mRNA expression increased significantly 
by 52.8±9.7 fold compared to the non-
metastasis group (p = 0.005). However, 
there was no significantly differrence 
in CXCL12 mRNA expression between 
samples with primary tumor size <2 cm in 
both groups (p = 0.800). Schnitt & Guidi,29 
reported that there is a linear relationship 
between tumor size and axillary lymph 
node involvement. Patients with lymph 
nodes containing tumor size >2 cm have 
a worse prognosis compared to patients 
with tumor size <2cm.30    Tumor size 
has  been  investigated as a consistent 
prognostic factor after lymph node 
status in breast carcinoma. Chang et 
al.31 reported that large tumors (> 5 cm) 
with negative lymph nodes have a better 
prognosis than those with a tumor size of 
3 to 4.9 cm. Large-sized tumors without 
lymph node metastasis have a lower 
ability to settle. However, the increase 
oftumor size may increases recurrence. 
In this study, the mean level CXCL12 
mRNA expression without lymph node 
metastasis was lower (20.5±6.1 fold) 
compared to the lymph nodes with 
metastasis (52.8±9.7 fold). 
The expression of CXCL12 mRNA 
in lymph nodes with metastatic breast 
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carcinoma tended to occur in those 
aged > 45 yr (TABLE 2). The difference 
of mean CXCL12 mRNA expression 
wassignificantly (p=0.012) higher in 
lymph nodes with metastasis (53.8±11.1 
fold) than without metastasis (21.1±7.0 
fold). However, no significant differences 
in CXCL12 mRNA expression between 
age ≤45 yr and > 45 yr was observed 
among each group (TABLE 3). This study 
used a wide age range, with a median 
age of 51 yr (32 – 79 yr). Kim, et al.32 
reported that there is no significant 
relationship between the expression of 
SDF-1α  protein  with the  patient’s age.
Sun et al.11 reported that there is 
no significant correlation between 
CXCL12 protein expression with age and 
menopausal status. Women aged above 
50 yr are more at risk to suffer from breast 
carcinoma compared with women aged 
under 50 yr.33 Breast tumor at age >45 
yrexpressed more ER. This may be due 
to decreased  estrogen levels and thus 
upregulate the receptor.34 The decline in 
blood  estrogen at the time of menopause, 
causes the sensitized stem cells to activate 
the local estrogen synthesis mechanism. 
This would induce proliferation and 
genetic dysfunction.35 CXCL12 has been 
investigated as estrogen-regulated genes 
in ovarian and breast cancer cells with 
positive ER through a direct path in 
which estrogen induces the production 
of CXCL12 through ER.36
Several limitations were present in 
this study. Firstly, we did not determine 
the level of axillary lymph nodes, which 
the number of involved lymph nodes 
and the level of involvement (level I, 
II or III) were independent predictive 
factor for survival.37  Secondly, the 
different duration of sample’s storage 
acquired from 2014 to 2015 were 
probably inappropriate. Thirdly, we 
did not distinguish between lymph 
nodes with sinus histiocytosis or 
follicular hyperplasia as the possible 
reaction of tumor cell metastasis. 
Finally, the number of sample was not 
sufficiently large, which could impact 
the robustness of the statistical result. 
This study provided preliminary data 
of CXCL12 mRNA expression of lymph 
node with metastasis breast cancer in 
the Indonesian population. Further 
extensive  studies of chemokines in 
lymph node dan breast cancer especially 
in Indonesia are required for appropriate 
therapeutic strategy.
CONCLUSION
The present study suggests that the 
higher CXCL12 mRNA expression level 
is associated with bigger tumor size and 
poor differentiation in breast cancer 
patients with lymph nodes metastasis.
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